Neumora Therapeutics, Inc.
NMRA
$1.28
-$0.12-8.57%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -58.82M | -72.55M | -58.70M | -53.72M | -108.73M |
| Total Depreciation and Amortization | 157.00K | 156.00K | 160.00K | 158.00K | 166.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 9.68M | 9.47M | 11.42M | 7.02M | 70.23M |
| Change in Net Operating Assets | -1.36M | 29.43M | -9.03M | 3.59M | -13.11M |
| Cash from Operations | -50.34M | -33.48M | -56.16M | -42.96M | -51.44M |
| Capital Expenditure | 775.00K | 0.00 | 0.00 | -775.00K | -44.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -99.57M | 156.99M | 21.26M | -149.23M | 13.72M |
| Cash from Investing | -98.80M | 156.99M | 21.26M | -150.00M | 13.68M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 15.35M | 1.76M | 2.65M | 1.85M | 339.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | 0.00 |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 225.00K | -225.00K | -- | -- | -820.00K |
| Cash from Financing | 15.57M | 1.53M | 2.65M | 1.85M | -481.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -133.57M | 125.04M | -32.25M | -191.11M | -38.25M |
